The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
Through enhanced insights into atherosclerotic disease, complex coronary lesions and coronary stents, photon-counting CT provides an anatomical roadmap that may improve outcomes for interventional procedures.
In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
A high glandular tissue component on pre-op breast ultrasound may significantly elevate the risk of recurrence for ipsilateral or contralateral breast cancer, according to a newly published study.